As 2024 ends, Cytonics reflects on remarkable progress in developing their drug CYT-108 for osteoarthritis treatment. The first clinical trial began, greatly aided by a team of orthopedic specialists. Plans for Phase 2 trials are underway, with fundraising efforts expected in early 2025 to support research and development.
